Latest News

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2025

Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...

View Article

Richmond wins a Most Loved Workplace Award for committing to a people-first culture

March 2025

Richmond has been recognised as a great place to work and as one of the Breakthrough Culture Award winners for 2024.

View Article

Richmond Supports Groundbreaking Study in Alpha-1 Antitrypsin Deficiency (AATD) with Beam Therapeutics

March 2025

Richmond congratulates Beam Therapeutics on the preliminary results from the first three dose levels of its ongoing Phase 1/2 study...

View Article

First patient enrolled in telehealth study, the Pathway Study

February 2025

The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...

View Article

Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

February 2025

We are committed to embedding Environmental, Social, and Governance (ESG) principles into our clinical research operations to drive responsible and sustainable business growth...

View Article

Trial That Could Revolutionise Cardiac Safety Studies – Research Consortium Calls For Others To Join

February 2025

The US-based Cardiac Safety Research Consortium has endorsed a project aimed at replacing the routine use of drugs...

View Article

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026

Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).

Clinical Trials Innovation Programme

10 - 11 February 2026

Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.

View event

Low data variability

Exceptional ECG generation

Experts in cardiac safety

Our specialist services

サービス一覧

News

Stay up to date with the latest activity at Richmond Pharmacology

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

Richmond wins a Most Loved Workplace Award for committing to a people-first culture

Richmond Supports Groundbreaking Study in Alpha-1 Antitrypsin Deficiency (AATD) with Beam Therapeutics

First patient enrolled in telehealth study, the Pathway Study

Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

Trial That Could Revolutionise Cardiac Safety Studies – Research Consortium Calls For Others To Join

Meet the experts

Careers at Richmond

Our Videos

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

Events

Clinical Trials Innovation Programme

About us

Knowledge Base

Connect with us